Tatva Chintan Pharma Chem Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/mbh9ucs7lzo9jsfot04epgda.pdf

Key Takeaways


The Margin Squeeze: Volume Is the Only Cure

Chintan Shah: "The current issue lies with the overall operational expenses, which are spread across smaller volumes. However, as soon as there is an increase in volume, we can expect to see a significant and positive impact on our profit margins."

PASC: The Near-Term Growth Engine


PTCs: New Customers, New Application, Slow Ramp

Chintan Shah: "This is basically getting into some kind of specialty polymer. And theoretically speaking, if I can just largely say it is kind of a recyclable plastic application where they are using."

SDAs: Cyclical Bottom, Green Shoots Visible

Chintan Shah: "They are discouraging the use of EV, and this will have a positive impact on the business of SDAs."

Electrolyte Salts & Energy Storage: A Unique Position Taking Shape

Chintan Shah: "This is a very exciting development for us which can lead us to a very unique position wherein we make the salts ourselves and are also able to formulate the electrolyte ourself. This will give us a unique competitive advantage and a potential to significantly increase our presence in the segment of energy storage."

Semiconductor & High-Purity: The Three-Year Bet

Chintan Shah: "If this works through, probably we will be the first company in India to have qualified for these grades of high-purity semiconductor material."

Guidance & Commitments

CommitmentSpecificsTimeline
PASC revenueAt least ₹80–100 crores revenueNext year (FY26)
PASC margin recoveryEBITDA margins become "much healthier"Once volumes hit from May 2025
Existing plant full utilizationAlmost fully occupiedJune or July 2025
New plant operationalDahej plant ready for productionQ4 FY2026 / January 2026
SDA commercial suppliesTwo large customers begin suppliesApril 2025
Electrolyte formulation pilotPilot scale runApril 2025
Photochlorination shipmentsFirst shipments beginApril 2025
PASC largest productsRegular shipments rolling outApril or May 2025
Monoglyme commercialisationInstallation and commercialisationJune 2025
Polymer first shipmentFirst shipment dispatchedMid-February 2025
Semiconductor-grade TMAHCrack below 1 PPB thresholdWithin 4–6 months
Pharma intermediates (3 products)Gradual commercialisation beginsEnd of 2025 or early 2026
Pharma intermediate (4th product)CommercialisationEnd of next calendar year
PTC new customer rampBusiness stabilizes, then "quite significant jump"6–8 months from now

Key Metrics

MetricQ3 FY25
Revenue from operations₹85.9 cr, 2% YoY growth and 3% QoQ growth
EBITDA₹7.1 cr, 36% decline YoY but 26% increase QoQ
EBITDA margin8.2%, vs 13.1% in Q3 FY24; COGS up 4.0% YoY and other expenses up 1.1% YoY
PAT₹0.14 cr, vs ₹3.5 cr in Q3 FY24; PAT margin 0.2% vs 4.1%
Exports₹52.8 cr, 61% of revenue
PTC segment revenue₹29.5 cr, 19% YoY growth and 7% QoQ growth
Electrolyte Salts segment revenue₹2.5 cr, 113% YoY growth and 101% QoQ growth
Pharma and Agro Intermediates and Specialty Chemicals revenue₹29.8 cr, 18% YoY growth and 10% QoQ growth
Raw material consumption44–45% of sales, consistent
Gross profit margin52% currently; guided to stabilize at roughly 45% as product mix shifts
Goods in transit~₹11 cr, similar to ~₹10–11 cr at end of Q2 FY25; U.S. transit 8–9 weeks, Europe 7–8 weeks
Distillation plant capacity freedAt least 12–15% of plant space, operational from January 2025
PASC segment revenue guidance (FY26)At least ₹80–100 cr
Semiconductor-grade TMAH trace metals38–60 PPB currently; target below 1 PPB; have recorded 30 PPB